Literature DB >> 11471095

Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis.

R P Garofalo1, J Patti, K A Hintz, V Hill, P L Ogra, R C Welliver.   

Abstract

It has been suggested that the pathogenesis of respiratory syncytial virus (RSV) infection is related to the development of T helper (Th) type 2 cytokine responses. The presence of Th1 and Th2 cytokines and the chemokines macrophage inflammatory protein (MIP)-1alpha and monocyte chemotactic protein (MCP)-1 were assessed by ELISA in nasopharyngeal secretions of infants with RSV infection. Infants with mild bronchiolitis had increased Th1 cytokines and reduced Th2 cytokines, compared with infants with upper respiratory tract illness alone. Severe bronchiolitis was characterized by a more balanced Th1-Th2 response that did not differ from that of infants with upper respiratory tract illness alone. In contrast, MIP-1alpha was markedly increased in infants with severe bronchiolitis. MIP-1alpha and MCP-1 levels also were inversely related to oxygen saturation (P<.005). Thus, the severity of RSV bronchiolitis appears to be related more to chemokine release than to Th2 cytokine production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471095     DOI: 10.1086/322788

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  81 in total

1.  TAK1 regulates NF-ΚB and AP-1 activation in airway epithelial cells following RSV infection.

Authors:  Nilay Dey; Tianshuang Liu; Roberto P Garofalo; Antonella Casola
Journal:  Virology       Date:  2011-08-10       Impact factor: 3.616

2.  Cigarette smoke condensate enhances respiratory syncytial virus-induced chemokine release by modulating NF-kappa B and interferon regulatory factor activation.

Authors:  Shawn Monique Castro; Deepthi Kolli; Antonieta Guerrero-Plata; Roberto P Garofalo; Antonella Casola
Journal:  Toxicol Sci       Date:  2008-08-22       Impact factor: 4.849

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 4.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 5.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state.

Authors:  Sif Hansdottir; Martha M Monick; Nina Lovan; Linda Powers; Alicia Gerke; Gary W Hunninghake
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

Review 7.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

8.  Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus.

Authors:  Srikanth Kota; Ahmed Sabbah; Te Hung Chang; Rosalinda Harnack; Yan Xiang; Xiangzhi Meng; Santanu Bose
Journal:  J Biol Chem       Date:  2008-06-20       Impact factor: 5.157

Review 9.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo.

Authors:  Cynthia A Bonville; Vincent K Lau; Jordana M DeLeon; Ji-Liang Gao; Andrew J Easton; Helene F Rosenberg; Joseph B Domachowske
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.